Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Raw Materials (2021 - 2024)

Apellis Pharmaceuticals filings provide 4 years of Raw Materials readings, the most recent being $42.1 million for Q1 2024.

  • For the quarter ending Q1 2024, Raw Materials rose 23.98% year-over-year to $42.1 million, compared with a TTM value of $42.1 million through Mar 2024, up 23.98%, and an annual FY2023 reading of $32.7 million, up 9.64% over the prior year.
  • Raw Materials hit $42.1 million in Q1 2024 for Apellis Pharmaceuticals, up from $32.7 million in the prior quarter.
  • The five-year high for Raw Materials was $42.1 million in Q1 2024, with the low at $5.7 million in Q4 2021.
  • Median Raw Materials over the past 4 years was $28.0 million (2022), compared with a mean of $26.3 million.
  • The sharpest move saw Raw Materials surged 419.17% in 2022, then grew 0.75% in 2023.
  • Year by year, Raw Materials stood at $5.7 million in 2021, then skyrocketed by 419.17% to $29.8 million in 2022, then increased by 9.64% to $32.7 million in 2023, then increased by 28.62% to $42.1 million in 2024.
  • According to Business Quant data, Raw Materials over the past three periods came in at $42.1 million, $32.7 million, and $26.2 million for Q1 2024, Q4 2023, and Q3 2023 respectively.